Wearable Biomarkers Move from Passive Tracking to Clinical Decision Support
Digital therapeutics is shifting from software that simply records symptoms to systems that can interpret physiology in near real time. A 2026 structured narrative review in Bioengineering examines how wearable electronic devices, machine learning, and artificial intelligence are converging into a single clinical workflow built around digital biomarkers. The central argument is straightforward: biometric streams only become clinically meaningful when they are technically verified, biologically plausible, and externally validated against outcomes that matter in practice.
The review focuses on heart rate variability, or HRV, as the clearest example of a wearable-derived signal with translational promise. HRV sits at the intersection of autonomic regulation, stress physiology, and disease monitoring, which makes it attractive for digital health applications across cardiovascular, neurological, metabolic, and psychiatric conditions. Biomarkers such as cortisol, salivary alpha-amylase, and interleukins also enter the picture because they can help link device output to biological stress responses rather than isolated numerical patterns.
A single high-performing model is not the same thing as a clinically useful one.
Why Physiologic Signals Need More Than Raw Accuracy
The review draws a hard line between pattern recognition and patient care. In controlled settings, machine-learning systems built on wearable data frequently reached classification accuracies above 85%, but those results do not automatically translate into bedside utility. Small gains in internal validation can disappear when a model is exposed to movement artifacts, missing data, sensor drift, or a population that differs from the training set in age, sex, comorbidity burden, or medication exposure.
That distinction matters most in ambulatory care, where data quality is inherently unstable. A wearable that performs well in a laboratory may behave very differently when used during exercise, sleep disruption, daily work, or acute illness. The review treats artifact reduction as a core clinical engineering problem rather than a technical afterthought, because noisy input can distort downstream risk estimates, symptom classification, and treatment recommendations.
In practical terms, the authors argue that wearable outputs should not be called biomarkers until they pass both technical verification and clinical validation. This requirement is especially important for digital therapeutics that aim to support screening, monitoring, or adaptive intervention rather than simple wellness tracking. Without that filter, there is a risk of building elegant systems that generate convincing numbers without delivering reliable decisions.
HRV, Stress Biology, and the Search for Actionable Endpoints
HRV occupies a central role because it captures autonomic nervous system balance in a way that may reflect stress load, recovery, and disease trajectory. The review links HRV with biochemical markers including cortisol, salivary alpha-amylase, and interleukins to show how multimodal sensing can strengthen interpretability. A digital platform that tracks only one signal may miss the biology behind a symptom flare, while a multimodal system can better map physiology to clinical state.
This is where digital therapeutics becomes more than a data dashboard. If a wearable captures a reproducible decline in autonomic variability alongside a stress biomarker pattern, it can support earlier behavioral interventions, closer surveillance, or escalation of care before a clinical event becomes obvious. The review places particular emphasis on the ability of continuous monitoring to broaden access to care while enabling more individualized management strategies.
Still, biological plausibility alone is not enough. A model may appear accurate because it is learning shortcuts from a narrow dataset rather than a true disease signature. That risk becomes more serious when the training cohort is small, homogeneous, or drawn from a single setting. A system built on such data may look strong in development and then fail when applied to patients whose physiologic patterns do not match the original cohort.
Machine Learning Improves Signal Quality, But Generalizability Remains the Barrier
The paper devotes substantial attention to methods that can strengthen wearable analytics, especially LSTM and GAN architectures for handling variable ambulatory data. These tools can help reduce artifacts, reconstruct missing segments, and improve the stability of sequence-based predictions. In principle, that makes them well suited to continuous physiologic monitoring, where the signal is often fragmented and heavily influenced by context.
Yet the review does not present algorithmic sophistication as a substitute for validation. Models trained on idealized datasets may struggle once deployed in the real world, where sensor placement differs, daily routines vary, and physiologic baselines shift over time. Clinical utility depends not only on accuracy but also on calibration, interpretability, and reproducibility across settings.
Demographic-aware modeling is presented as a necessary next step. Wearable-derived algorithms need to account for differences in age, sex, comorbidity, and other population factors that can change physiologic expression. Without that adjustment, a system may underperform in the very groups most likely to benefit from remote monitoring, early detection, or personalized digital therapy.
Privacy, Equity, and the Clinical Cost of Weak Validation
The review also addresses the infrastructure needed for responsible deployment. Federated learning appears as one strategy for privacy-preserving model development, allowing systems to improve across decentralized datasets without forcing all patient information into a single repository. For clinical adoption, that matters because data governance can determine whether institutions are willing to participate at scale.
Equity remains an unresolved issue throughout the paper. If wearable and AI systems are trained predominantly on narrow populations, they can reproduce the same disparities that already limit access to precision medicine. A device that performs well for one demographic group but poorly for another may widen care gaps while appearing technologically advanced. The review argues for external validation in diverse populations precisely to prevent that outcome.
A model that fails silently in underrepresented patients is a safety problem, not a software flaw.
What Clinicians Should Take from the Review
The most useful contribution of this review is its insistence that digital biomarkers occupy a higher evidentiary bar than consumer wellness metrics. HRV and related signals may prove clinically valuable, but only if they are tied to robust physiology, validated across populations, and embedded in workflows that account for noise, bias, and real-world variability. In that framework, wearable monitoring is not a replacement for clinical judgment; it is a potential extension of it.
The article points toward a future in which digital therapeutics can support early detection, longitudinal monitoring, and proactive intervention across multiple disease states. Even so, the path to routine use remains contingent on external validation, demographic representativeness, and privacy-preserving deployment models that can survive outside the research environment. The next proof point will not be another high internal accuracy score, but evidence that these systems improve decisions in heterogeneous patients under everyday clinical conditions.